Phase Ⅱ Clinical Trial of Neoadjuvant Arterial Embolization Chemotherapy Combined Immune Checkpoint Inhibitor for Locally Advanced Rectal Cancer: A Single Arm Prospective Sturdy
Latest Information Update: 15 May 2023
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Oxaliplatin (Primary) ; Raltitrexed (Primary) ; Tislelizumab (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- Acronyms NECI
- 17 Oct 2022 Planned End Date changed from 31 Aug 2025 to 31 Oct 2025.
- 17 Oct 2022 Planned primary completion date changed from 30 Sep 2024 to 30 Nov 2024.
- 17 Oct 2022 Status changed from not yet recruiting to recruiting.